-
BMC Cancer. 2017 Mar 23;17(1):211. doi: 10.1186/s12885-017-3196-6.
Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy
Kim ST11, Lee J1, Park SH1, Park JO1, Park YS1, Kang WK1, Lim HY2.
View PubMed
-
Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669.
Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition
Kim ST11, Kim SY1, Klempner SJ2,3, Yoon J4, Kim N4, Ahn S4,5, Bang H5,6, Kim KM5,6, Park W4, Park SH1, Park JO1, Park YS1, Lim HY1, Lee SH1, Park K1,6, Kang WK1, Lee J1.
View PubMed
-
Oncotarget. 2017 Feb 14;8(7):11094-11104. doi: 10.18632/oncotarget.14362.
Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer
Kim JH11, Lee SH2, Choi S2, Kim U3, Yeo IS4, Kim SH2, Oh MJ3, Moon H3, Lee J3, Jeong S3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Min YW5, Lee H5, Lee JH5, Rhee PL5, Kim JJ5, Lee SJ5, Kim ST5, Lee J5, Park SH5, Park JO5, Park YS5, Lim HY5, Kang WK5, An HJ3, Kim JH4.
View PubMed
-
Oncotarget. 2017 Feb 28;8(9):15014-15022. doi: 10.18632/oncotarget.14788.
Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion
Kim SY11, Ahn T2, Bang H3, Ham JS1, Kim J1, Kim ST1, Jang J1, Shim M1, Kang SY3, Park SH1, Min BH4, Lee H4, Kang WK1, Kim KM3, Park W2,5, Lee J1.
View PubMed
-
Oncotarget. 2017 Feb 21;8(8):13320-13328. doi: 10.18632/oncotarget.14519.
Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability
Cho J11, Lee J2, Bang H3, Kim ST2, Park SH2, An JY4, Choi MG4, Lee JH4, Sohn TS4, Bae JM4, Kang WK2, Kim S4, Kim KM3.
View PubMed
-
Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700.
The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors
Lim SH11, Kim SY1, Kim K2, Jang H1, Ahn S2, Kim KM2, Kim NK3, Park W3, Lee SJ1, Kim ST1, Park SH1, Park JO1, Park YS1, Lee SH1, Lim HY1, Park K1, Kang WK1, Lee J1.
View PubMed
-
Am J Ther. 2016 Nov/Dec;23(6):e1449-e1455.
A Prognostic Index to Identify Patients With Intrahepatic Cholangiocarcinoma Who Could Benefit From Gemcitabine Plus Cisplatin
Lee SY11, Kim HS, Choi YJ, Park KH, Shin SW, Kim YH, Tae Kim S.
View PubMed
-
Transl Oncol. 2016 Oct;9(5):466-471. doi: 10.1016/j.tranon.2016.08.009.
Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma
Cho J11, Lee J1, Kim J1, Kim ST1, Lee S1, Kim SY1, Ha SY2, Park CK3, Lim HY4.
View PubMed
-
J Cancer. 2016 Oct 25;7(15):2173-2178. eCollection 2016.
To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients
Lee H11, Lee J2, Sohn I3, Park SH2, Park JO2, Park YS2, Kim KM4, Kang WK2, Kim ST2.
View PubMed
-
Oncotarget. 2016 Sep 20;7(38):62676-62686. doi: 10.18632/oncotarget.10445.
Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy
Yu JI11, Lee H2, Park HC1, Choi DH1, Choi YL3, Do IG4, Kim HC5, Lee WY5, Yun SH5, Cho YB5, Huh JW5, Park YA6, Park YS6, Park JO6, Kim ST6, Park W1.
View PubMed
-
Mod Pathol. 2016 Sep;29(9):1095-103. doi: 10.1038/modpathol.2016.96. Epub 2016 May 27.
FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival
Ahn S11,2, Lee J3, Hong M4, Kim ST3, Park SH3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Jung SH6, Kang WK3, Kim KM1,2.
View PubMed
-
Mol Diagn Ther. 2016 Aug;20(4):375-83. doi: 10.1007/s40291-016-0205-4.
A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer
Ahn S11,2, Hong M3, Van Vrancken M4, Lyou YJ2, Kim ST5, Park SH5, Kang WK5, Park YS5, Jung SH6, Woo M6, Lee J7, Kim KM8,9.
View PubMed
-
Transl Oncol. 2016 Jun;9(3):173-8. doi: 10.1016/j.tranon.2016.01.007. Epub 2016 Apr 22.
Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing
Yoo KH11, Kim NK2, Kwon WI3, Lee C2, Kim SY1, Jang J1, Ahn J1, Kang M1, Jang H1, Kim ST1, Ahn S4, Jang KT4, Park YS1, Park WY5, Lee J6, Heo JS7, Park JO8.
View PubMed
-
J Cancer Res Clin Oncol. 2016 Jun;142(6):1231-7. doi: 10.1007/s00432-016-2143-2. Epub 2016 Mar 16.
Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin)
Kim ST11, Ahn S2, Lee J1, Lee SJ1, Park SH1, Park YS1, Lim HY1, Kang WK1, Kim KM2, Park JO3.
View PubMed
-
Transl Oncol. 2016 Jun;9(3):197-202. doi: 10.1016/j.tranon.2016.03.008. Epub 2016 May 12.
BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells
Kim HK11, Kim SY1, Lee SJ1, Kang M1, Kim ST1, Jang J1, Rath O2, Schueler J2, Lee DW3, Park WY4, Kim SJ5, Park SH1, Lee J6.
View PubMed
-
Onco Targets Ther. 2016 Jun 1;9:3307-12. doi: 10.2147/OTT.S104511. eCollection 2016.
The prognostic role of serum C-X-C chemokine receptor type 4 in patients with metastatic or recurrent colorectal cancer
Choi YJ11, Chang WJ1, Shin SW1, Park KH1, Kim ST2, Kim YH1.
View PubMed
-
J Cancer. 2016 May 25;7(9):1044-8. doi: 10.7150/jca.14815. eCollection 2016.
Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era
Kim ST11, Lee SJ1, Park SH1, Park JO1, Lim HY1, Kang WK1, Lee J1, Park YS1.
View PubMed
-
Cancer Chemother Pharmacol. 2016 May;77(5):979-85. doi: 10.1007/s00280-016-3014-x. Epub 2016 Mar 26.
Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma
Kim YS11, Hwang IG2, Park SE3, Go SI4, Kang JH4, Park I1, Oh SY5, Ji JH6, Song HN7, Park SH7, Kim ST7, Park JO7.
View PubMed
-
Medicine (Baltimore). 2016 May;95(19):e3534. doi: 10.1097/MD.0000000000003534.
The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution
Kim ST11, Ha SY, Lee J, Hong SN, Chang DK, Kim YH, Park YA, Huh JW, Cho YB, Yun SH, Lee WY, Kim HC, Park YS.
View PubMed
-
Oncotarget. 2016 Apr 12;7(15):19610-9. doi: 10.18632/oncotarget.7526.
Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment
Song HN11,2, Lee C3,4, Kim ST1, Kim SY1, Kim NK3, Jang J1, Kang M1, Jang H1, Ahn S5, Kim SH5, Park Y6, Cho YB6, Heo JW6, Lee WY6, Park JO1, Lim HY1, Kang WK1, Park YS1, Park WY3,7,4, Lee J1, Kim HC6.
View PubMed
-
Oncotarget. 2016 Apr 26;7(17):24088-96. doi: 10.18632/oncotarget.8175.
Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
Kim ST11, Lee J1, Lee SJ1, Park SH1, Jung SH2, Park YS1, Lim HY1, Kang WK1, Park JO1.
View PubMed
-
Cancer Res Treat. 2016 Apr;48(2):553-60. doi: 10.4143/crt.2015.155. Epub 2015 Aug 10.
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
Yi JH11, Kang JH2, Hwang IG3, Ahn HK4, Baek HJ5, Lee SI5, Lim DH5, Won YW6, Ji JH7, Kim HS8, Rha SY8, Oh SY9, Lee KE10, Lim T11, Maeng CH12, Kim MJ13, Kim ST13, Lee J13, Park JO13, Park YS13, Lim HY13, Kang WK13, Park SH13.
View PubMed
-
J Cancer. 2016 Feb 5;7(5):484-9. doi: 10.7150/jca.13711. eCollection 2016.
The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs
Kim ST11, Ha SY2, Lee S1, Ahn S2, Lee J1, Park SH1, Park JO1, Lim HY1, Kang WK1, Kim KM2, Park YS1.
View PubMed
-
BMC Cancer. 2016 Feb 18;16:120. doi: 10.1186/s12885-016-2141-4.
The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis
Kim HS11,2, Heo JS3, Lee J4, Lee JY5, Lee MY6, Lim SH7, Lee WY8, Kim SH9, Park YA10, Cho YB11, Yun SH12, Kim ST13, Park JO14, Lim HY15, Choi YS16, Kwon WI17, Kim HC18, Park YS19.
View PubMed
-
Oncotarget. 2016 Jan 26;7(4):4024-35. doi: 10.18632/oncotarget.6602.
Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors
Park C11, Ha SY1, Kim ST2, Kim HC3, Heo JS3, Park YS2, Lauwers G4, Lee J2, Kim KM1.
View PubMed
-
Cancer Res Treat. 2016 Jan;48(1):153-61. doi: 10.4143/crt.2014.183. Epub 2015 Mar 7.
The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors
Kim M11, Lee S2, Lee J2, Park SH2, Park JO2, Park YS2, Kang WK2, Kim ST2.
View PubMed
-
Oncotarget. 2015 Nov 24;6(37):40026-35. doi: 10.18632/oncotarget.5432.
PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA
Kim ST11, Lira M2, Deng S2, Lee S1, Park YS1, Lim HY1, Kang WK1, Mao M3, Heo JS4, Kwon W4, Jang KT5, Lee J1,6, Park JO1,6.
View PubMed
-
Oncotarget. 2015 Nov 17;6(36):39028-35. doi: 10.18632/oncotarget.5494.
NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line
Lee SJ11, Li GG2, Kim ST1, Hong ME3, Jang J1, Yoon N3, Ahn SM3, Murphy D2, Christiansen J2, Wei G2, Hornby Z2, Lee DW4, Park JO1,5, Park YS1, Lim HY1, Hong SN6, Kim SH3, Kang WK1, Park K1, Park WY7, Kim KM3,5, Lee J1.
View PubMed
-
Br J Cancer. 2015 Nov 17;113(10):1421-6. doi: 10.1038/bjc.2015.371. Epub 2015 Oct 27.
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer
Lim SH11, Kim TW2, Hong YS2, Han SW3, Lee KH3, Kang HJ4, Hwang IG5, Lee JY1, Kim HS1, Kim ST1, Lee J1, Park JO1, Park SH1, Park YS1, Lim HY1, Jung SH6,7, Kang WK1.
View PubMed
-
Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465.
Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients
Kim ST11, Lee WS2, Lanman RB3, Mortimer S3, Zill OA3, Kim KM4,5, Jang KT5, Kim SH5, Park SH1, Park JO1,4, Park YS1, Lim HY1, Eltoukhy H3, Kang WK1, Lee WY6, Kim HC6, Park K1,4, Lee J1,4, Talasaz A3.
View PubMed
-
J Clin Oncol. 2015 Oct 1;33(28):3130-6. doi: 10.1200/JCO.2014.58.3930. Epub 2015 Jan 5.
Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses
Park SH11, Sohn TS1, Lee J1, Lim DH1, Hong ME1, Kim KM1, Sohn I1, Jung SH1, Choi MG1, Lee JH1, Bae JM1, Kim S1, Kim ST1, Park JO1, Park YS1, Lim HY1, Kang WK2.
View PubMed
-
Cancer Res Treat. 2015 Oct;47(4):790-5. doi: 10.4143/crt.2014.126. Epub 2014 Dec 2.
Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
Kim ST11, Kim TW2, Kim KP2, Kim TY3, Han SW3, Lee JY1, Lim SH1, Lee MY1, Kim H1, Park YS1.
View PubMed
-
BMC Cancer. 2015 Oct 20;15:747. doi: 10.1186/s12885-015-1759-y.
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
Kim ST1, Ahn TJ, Lee E, Do IG, Lee SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim SH, Lee J, Kim HC
View PubMed
-
Radiother Oncol. 2015 Oct;117(1):171-7. doi: 10.1016/j.radonc.2015.08.009. Epub 2015 Aug 20.
Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial
Yu JI11, Lim do H2, Ahn YC1, Lee J3, Kang WK3, Park SH3, Park JO3, Park YS3, Lim HY3, Kim ST3, Kim S4, Sohn TS4, Choi MG4, Bae JM4, Nam H5.
View PubMed
-
Int J Biol Markers. 2015 Nov 11;30(4):e382-6. doi: 10.5301/jbm.5000151.
Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer
Lee SJ11, Lee J1, Kim ST1, Park SH1, Park JO1, Park YS1, Lim HY1, Kang WK1.
View PubMed
-
Cancer Res Treat. 2015 Oct;47(4):796-803. doi: 10.4143/crt.2014.106. Epub 2015 Jan 30.
Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer
Kim ST11,2, Chang WJ1, Jin L3, Sung JS3, Choi YJ1, Kim YH1,3.
View PubMed
-
Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188.
The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis
Kim ST11, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.
View PubMed
-
Oncotarget. 2015 Sep 15;6(27):24320-32.
Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening
Lee J11, Kim HC2, Hong JY3, Wang K4, Kim SY1, Jang J1, Kim ST1, Park JO1, Lim HY1, Kang WK1, Park YS1, Lee J1, Lee WY2, Park YA2, Huh JW2, Yun SH2, Do IG5, Kim SH5, Balasubramanian S4, Stephens PJ4, Ross JS4,6, Li GG7, Hornby Z7, Ali SM4, Miller VA4, Kim KM5,8, Ou SH9.
View PubMed
-
Oncotarget. 2015 Sep 29;6(29):28211-22. doi: 10.18632/oncotarget.4721.
Gastrointestinal malignancies harbor actionable MET exon 14 deletions
Lee J11,2, Ou SH3, Lee JM4, Kim HC5, Hong M6, Kim SY1, Jang J1, Ahn S6, Kang SY6, Lee S1, Kim ST1, Kim B4, Choi J4, Kim KA4, Lee J1, Park C1,6, Park SH1, Park JO1,2, Lim HY1, Kang WK1, Park K1,2, Park YS1, Kim KM2,6.
View PubMed
-
Oncotarget. 2015 Sep 22;6(28):25619-30. doi: 10.18632/oncotarget.4627.
Patient-derived cell models as preclinical tools for genome-directed targeted therapy
Lee JY11, Kim SY1, Park C1, Kim NK2, Jang J1, Park K2, Yi JH3, Hong M4,5, Ahn T2, Rath O6, Schueler J6, Kim ST1, Do IG5, Lee S1, Park SH1, Ji YI7, Kim D7, Park JO1,4, Park YS1, Kang WK1, Kim KM4,5, Park WY2,7, Lim HY1, Lee J1,4.
View PubMed
-
Transl Oncol. 2015 Aug;8(4):288-94. doi: 10.1016/j.tranon.2015.06.001.
Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer
Kim ST11, Jang HL2, Lee J1, Park SH1, Park YS1, Lim HY1, Choi MG3, Bae JM3, Sohn TS3, Noh JH3, Kim S3, Kim KM4, Kang WK1, Park JO5.
View PubMed
-
BMC Cancer. 2015 Jul 21;15:530. doi: 10.1186/s12885-015-1552-y.
Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer
Kim ST11, Jang KT2, Lee SJ3, Jang HL4, Lee J5, Park SH6, Park YS7, Lim HY8, Kang WK9, Park JO10.
View PubMed
-
Clin Transl Oncol. 2015 Jun;17(6):462-8. doi: 10.1007/s12094-014-1258-7. Epub 2014 Dec 2.
The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer
Kim ST11, Do IG, Lee J, Sohn I, Kim KM, Kang WK.
View PubMed
-
Nat Med. 2015 May;21(5):449-56. doi: 10.1038/nm.3850. Epub 2015 Apr 20.
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Cristescu R11, Lee J2, Nebozhyn M1, Kim KM3, Ting JC4, Wong SS4, Liu J4, Yue YG4, Wang J4, Yu K4, Ye XS4, Do IG3, Liu S5, Gong L5, Fu J6, Jin JG6, Choi MG7, Sohn TS7, Lee JH7, Bae JM7, Kim ST2, Park SH2, Sohn I8, Jung SH8, Tan P9, Chen R1, Hardwick J1, Kang WK2, Ayers M1, Hongyue D1, Reinhard C4, Loboda A1, Kim S7, Aggarwal A4.
View PubMed
-
Sci Rep. 2015 Mar 19;5:9289. doi: 10.1038/srep09289.
The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer
Lee JY11, Hong M2, Kim ST1, Park SH1, Kang WK1, Kim KM2, Lee J1.
View PubMed
-
Transl Oncol. 2015 Feb;8(1):40-6. doi: 10.1016/j.tranon.2014.12.003.
Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer
Kim ST11, Jang KT2, Lee J1, Jang HM3, Choi HJ4, Jang HL1, Park SH1, Park YS1, Lim HY1, Kang WK1, Park JO5.
View PubMed
-
Sci Rep. 2014 Dec 23;4:7592. doi: 10.1038/srep07592.
Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer
Yi JH11, Do IG2, Jang J3, Kim ST3, Kim KM4, Park SH3, Park JO3, Park YS3, Lim HY3, Kang WK3, Lee J3.
View PubMed
-
Eur J Cancer. 2014 Nov;50(16):2822-30. doi: 10.1016/j.ejca.2014.08.005. Epub 2014 Sep 15.
Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study
Kim ST11, Kang JH2, Lee J1, Park SH1, Park JO1, Park YS1, Lim HY1, Hwang IG3, Lee SC4, Park KW5, Lee HR6, Kang WK7.
View PubMed
-
BMC Cancer. 2014 Nov 26;14:883. doi: 10.1186/1471-2407-14-883.
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
Kim ST1, Hong YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Lee JW, Jo SJ, Park YS1.
View PubMed
-
Mol Cancer Ther. 2014 Nov;13(11):2527-36. doi: 10.1158/1535-7163.MCT-14-0255. Epub 2014 Sep 23.
Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification
Kim ST11, Jang HL2, Lee SJ1, Lee J1, Choi YL3, Kim KM3, Cho J4, Park SH1, Park YS1, Lim HY1, Yashiro M5, Kang WK1, Park JO6.
View PubMed
-
PLoS One. 2014 Nov 5;9(11):e111693. doi: 10.1371/journal.pone.0111693. eCollection 2014.
High-Throughput Sequencing and Copy Number Variation Detection Using Formalin Fixed Embedded Tissue in Metastatic Gastric Cancer
Kim S11, Lee J2, Hong ME3, Do IG3, Kang SY1, Ha SY1, Kim ST2, Park SH2, Kang WK2, Choi MG4, Lee JH4, Sohn TS4, Bae JM4, Kim S4, Kim DH5, Kim KM3.
View PubMed
-
Cancer?Genomics Proteomics.?2014 Sep-Oct;11(5):259-66.
Transcriptome Analysis of CD133-positive Stem Cells and Prognostic Value of Survivin in Colorectal Cancer
Kim ST11,?Sohn I2,?DO IG3,?Jang J4,?Kim SH3,?Jung IH5,?Park JO1,?Park YS1,?Talasaz A6,?Lee J1,?Kim HC7.
View PubMed
-
Cancer Res Treat. 2014 Jan;46(1):48-54. doi: 10.4143/crt.2014.46.1.48. Epub 2014 Jan 15.
Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients
Kim ST11, Park KH2, Shin SW2, Kim YH2.
View PubMed
